FDA sees growing interest, uptick in INDs containing nanomaterials
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsProduct Lifecycle